Biocon’s shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon’s seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.
Mark Mobius, pioneer of emerging markets investing, dies at 89
Mark Mobius, a pioneer of emerging markets investing, has died at 89. Known for decades at Franklin Templeton Investments, he championed opportunities across developing economies,